The Clotting Factor VIII Activity Test measures the activity of factor VIII, a protein essential for normal blood clotting. Low activity may indicate hemophilia A or acquired deficiencies, while elevated activity is linked to clotting risk. This test helps evaluate unexplained bleeding, bruising, or thrombosis, and supports diagnosis of inherited or acquired clotting disorders, providing insight into overall hemostatic function.

The Factor V Leiden Mutation Analysis detects a genetic mutation in the F5 gene that increases risk of abnormal blood clotting (thrombophilia). Individuals with this mutation may be prone to deep vein thrombosis (DVT), pulmonary embolism, or pregnancy complications. Doctors use this DNA test to confirm inherited clotting disorders, assess family risk, and guide prevention strategies, including anticoagulation or lifestyle management.

The von Willebrand Factor Antigen Test measures the amount of von Willebrand factor, a blood protein essential for clotting. Low levels may indicate von Willebrand disease, the most common inherited bleeding disorder, while elevated levels can occur with inflammation or pregnancy. Doctors use this test to evaluate unexplained bleeding, frequent nosebleeds, or heavy menstrual periods and to guide diagnosis and management of clotting disorders.

The Prothrombin with INR and Partial Thromboplastin Times Test measures how long blood takes to clot by evaluating PT, INR, and aPTT. Abnormal results may indicate clotting disorders, liver disease, vitamin K deficiency, or risk of bleeding and thrombosis. Doctors use this test to monitor patients on blood thinners like warfarin, assess unexplained bleeding, and evaluate clotting function. It provides critical insight into coagulation and overall blood health.

The Activated Protein C-Resistance Test evaluates how blood responds to activated protein C, helping identify resistance often caused by Factor V Leiden mutation. This test supports assessment of abnormal clotting, deep vein thrombosis, and inherited thrombophilia. By measuring clotting response, it provides insight into genetic risks, venous thromboembolism, and overall coagulation health.

The Prothrombin Time with INR Test measures how long it takes blood to clot and calculates the international normalized ratio (INR) for accuracy. It is commonly used to monitor patients on blood-thinning medications like warfarin and to evaluate bleeding disorders, liver disease, or vitamin K deficiency. Doctors order this test to investigate easy bruising, frequent nosebleeds, or prolonged bleeding and to ensure safe and effective anticoagulant therapy.

The Activated Partial Thromboplastin Time (aPTT) Test measures how long it takes blood to clot, evaluating clotting factors and overall coagulation function. Abnormal results may indicate bleeding disorders, hemophilia, liver disease, or clotting factor deficiencies. Doctors also use this test to monitor patients on heparin therapy. Results provide essential insight into blood clotting, bleeding risk, and treatment management for safe medical care.

The Antithrombin III Activity Test evaluates how effectively antithrombin controls clot formation in the blood. Reduced activity may indicate a hereditary deficiency, abnormal coagulation, or increased risk for venous thrombosis. This test provides insight into clotting disorders, supports diagnosis of thrombophilia, and helps assess vascular health and systemic risks related to impaired anticoagulant activity.

The Fibrinogen Activity Test measures how well fibrinogen, a key clotting protein, helps blood form clots. Low fibrinogen may indicate excessive bleeding, liver disease, or disseminated intravascular coagulation (DIC), while high levels may signal inflammation or increased clotting risk. Doctors use this test to evaluate unexplained bleeding, monitor clotting disorders, or assess liver function. Results provide vital insight into coagulation health and treatment management.

The Protein S Activity Test evaluates blood clot regulation by measuring the function of protein S, a vitamin K–dependent anticoagulant. Reduced activity may indicate inherited or acquired deficiency, leading to risk of venous thrombosis, pulmonary embolism, or recurrent clotting disorders. This test provides important insight into coagulation balance and is frequently used with other assays to clarify causes of abnormal clot formation and assess thrombotic risk.

The Cardio IQ™ Fibrinogen Antigen Test evaluates fibrinogen concentration, a key protein that influences clotting and cardiovascular disease risk. It provides insight into vascular inflammation, atherosclerosis, and thrombotic events. This test helps identify factors that contribute to stroke, coronary artery disease, and systemic vascular complications, offering valuable information for assessing overall cardiovascular health.

The Vitamin K Test measures blood levels of vitamin K, a nutrient essential for blood clotting, bone strength, and heart health. Deficiency may cause easy bruising, excessive bleeding, or weakened bones, and can result from poor diet, liver disease, or malabsorption. Doctors order this test to investigate clotting problems, monitor anticoagulant therapy, or assess nutritional status. Results help guide treatment, supplementation, and long-term health management.

The Cardiolipin IgM Antibody Test measures IgM antibodies linked to antiphospholipid syndrome and autoimmune disorders. It helps evaluate unexplained blood clots, recurrent miscarriages, or abnormal clotting events. By detecting immune system activity against phospholipids, this test supports the assessment of vascular health, autoimmune activity, and risks related to thrombosis or systemic lupus erythematosus.

The D-Dimer Test measures fragments of blood clots to help detect abnormal clotting activity. Elevated levels may indicate deep vein thrombosis (DVT), pulmonary embolism (PE), or disseminated intravascular coagulation (DIC). Doctors often order this test when patients have symptoms like leg pain, chest pain, or shortness of breath. Results provide vital insight into clotting risk, helping guide diagnosis and management of thrombotic disorders.

The Lupus Anticoagulant Evaluation with Reflex measures PTT-LA and dRVVT to detect lupus anticoagulant antibodies, which increase risk of abnormal clotting. Reflex tests such as Hexagonal Phase Confirmation, Thrombin Clotting Time, and dRVVT mixing are performed if results are prolonged. Doctors use this panel to evaluate unexplained clotting, recurrent miscarriage, or autoimmune disease, aiding in diagnosis of antiphospholipid syndrome.

The Beta-2-Glycoprotein I IgG IgA IgM Antibodies Test detects autoantibodies linked to antiphospholipid syndrome (APS), a disorder that increases risk of abnormal blood clotting. Measuring all three antibody classes provides a thorough evaluation of immune activity. Elevated results may be associated with recurrent miscarriages, venous or arterial thrombosis, and autoimmune conditions, supporting diagnosis and monitoring of clotting-related disorders.

The Methylenetetrahydrofolate Reductase (MTHFR) DNA Mutation Analysis detects genetic variants in the MTHFR gene that affect folate metabolism and homocysteine regulation. Mutations may increase risk for blood clots, cardiovascular disease, pregnancy complications, or certain neurological conditions. Doctors use this test to evaluate unexplained blood clotting, high homocysteine levels, or family history of related disorders.

The Cardiolipin IgG Antibody Test detects IgG antibodies to cardiolipin, often associated with autoimmune disease. Abnormal results may indicate antiphospholipid syndrome, blood clotting disorders, or pregnancy complications. This test provides insight into thrombotic risk, vascular health, systemic inflammation, and immune activity linked to autoimmune conditions and antibody-mediated disease.